Summarized by Masters of Longevity from Longevity Technology.
Magnitude Biosciences’ funding story — a news article about scaling a worm-based whole‑organism screening platform for faster, richer drug discovery.
Key Takeaways
- Magnitude Biosciences raised $1.3 million to commercialize its VivoScan whole‑organism screening platform.
- The company has delivered over 120 projects using WormGazer and VivoScan across drug discovery, nutrition, and aging biology.
- The funding round was led by Northstar Ventures and unlocked an additional £217,000 Innovate UK investor partnership grant.
